Jump to navigation Jump to search
Clinical data
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass239.267 g/mol

WikiDoc Resources for Flosequinan


Most recent articles on Flosequinan

Most cited articles on Flosequinan

Review articles on Flosequinan

Articles on Flosequinan in N Eng J Med, Lancet, BMJ


Powerpoint slides on Flosequinan

Images of Flosequinan

Photos of Flosequinan

Podcasts & MP3s on Flosequinan

Videos on Flosequinan

Evidence Based Medicine

Cochrane Collaboration on Flosequinan

Bandolier on Flosequinan

TRIP on Flosequinan

Clinical Trials

Ongoing Trials on Flosequinan at Clinical Trials.gov

Trial results on Flosequinan

Clinical Trials on Flosequinan at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Flosequinan

NICE Guidance on Flosequinan


FDA on Flosequinan

CDC on Flosequinan


Books on Flosequinan


Flosequinan in the news

Be alerted to news on Flosequinan

News trends on Flosequinan


Blogs on Flosequinan


Definitions of Flosequinan

Patient Resources / Community

Patient resources on Flosequinan

Discussion groups on Flosequinan

Patient Handouts on Flosequinan

Directions to Hospitals Treating Flosequinan

Risk calculators and risk factors for Flosequinan

Healthcare Provider Resources

Symptoms of Flosequinan

Causes & Risk Factors for Flosequinan

Diagnostic studies for Flosequinan

Treatment of Flosequinan

Continuing Medical Education (CME)

CME Programs on Flosequinan


Flosequinan en Espanol

Flosequinan en Francais


Flosequinan in the Marketplace

Patents on Flosequinan

Experimental / Informatics

List of terms related to Flosequinan

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Flosequinan is a quinolone vasodilator. It has direct relaxing effects on peripheral arteries and veins. It is administered orally in cases of congestive heart failure in patients who are not responsive to digitalis or ACE inhibitors. It was sold under the trade name Manoplax.

It was withdrawn from the US market in October 1993 due to an increased risk of hospitalization or death.[1]


Both methods for forming the heterocyclic ring in quinolones involved cyclization into the carbocyclic ring. A closely related quinolone that displays cardiovascular rather than antibiotic activity is constructed by a condensation that closes the bond at the 2,3 position in the heterocyclic ring.

700px U.S. Patent 5,079,264 N.B.[2]
700px U.S. Patent 5,079,264 N.B.[2]

The starting material (2) is obtained by reaction of the aminoacetophenone derivative (1) with ethyl formate. Heating the product in ethylene glycol methyl ether leads to an aldol-like cyclization and the formation of a quinolone ring. The product, flosequinan (3), displays vasodilator and cardiotonic activities.

See also


  1. "Heart drug withdrawn - Boots Pharmaceuticals' Manoplax". FDA Consumer. 1993. Retrieved 2008-12-01.
  2. http://www.druglead.com/cds/flosequinan.html